Tertiary Lymphoid Structures As Mediators of Immunotherapy Response

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Aug 12

PMID 35954412

Authors

Raj G Vaghjiani

Joseph J Skitzki

Affiliations

Soon will be listed here.

Abstract

Since its first application in the treatment of cancer during the 1800s, immunotherapy has more recently become the leading edge of novel treatment strategies. Even though the efficacy of these agents can at times be predicted by more traditional metrics and biomarkers, often patient responses are variable. TLS are distinct immunologic structures that have been identified on pathologic review of various malignancies and are emerging as important determinants of patient outcome. Their presence, location, composition, and maturity are critically important in a host's response to malignancy. Because of their unique immunogenic niche, they are also prime candidates, not only to predict and measure the efficacy of immunotherapy agents, but also to be potentially inducible gatekeepers to increase therapeutic efficacy. Herein, we review the mechanistic underpinnings of TLS formation, the data on its relationship to various malignancies, and the emerging evidence for the role of TLS in immunotherapy function.

Citing Articles

Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade.

Li Z, Liu S, Liu D, Yang K, Xiong J, Fang Z J Exp Clin Cancer Res. 2025; 44(1):84.

PMID: 40038799 PMC: 11881293. DOI: 10.1186/s13046-025-03318-6.

Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy.

Ciavattone N, Bevoor A, Farfel A, Rehman A, Ho K, Rock E Sci Rep. 2025; 15(1):5204.

PMID: 39939722 PMC: 11822021. DOI: 10.1038/s41598-025-89882-5.

Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma.

Chung S, Yeh Y, Huang C, Chiang N, Hsu D, Chan M J Immunother Cancer. 2025; 13(1).

PMID: 39870490 PMC: 11772930. DOI: 10.1136/jitc-2024-010173.

[Clinical significance of tertiary lymphoid structure maturity in colorectal cancer patients].

Zheng J, Yu J, Xie J, Chen D, Deng H Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024; 53(6):765-771.

PMID: 39628410 PMC: 11736343. DOI: 10.3724/zdxbyxb-2024-0320.

Machine Vision-Detected Peritumoral Lymphocytic Aggregates Are Associated With Disease-Free Survival in Patients With Papillary Thyroid Carcinoma.

Monabbati S, Fu P, Asa S, Pathak T, Willis J, Shi Q Lab Invest. 2024; 104(12):102168.

PMID: 39505213 PMC: 11659025. DOI: 10.1016/j.labinv.2024.102168.

References

Allen E, Jabouille A, Rivera L, Lodewijckx I, Missiaen R, Steri V . Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017; 9(385). PMC: 5554432. DOI: 10.1126/scitranslmed.aak9679. View

Petitprez F, De Reynies A, Keung E, Chen T, Sun C, Calderaro J . B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020; 577(7791):556-560. DOI: 10.1038/s41586-019-1906-8. View

Chaurio R, Anadon C, Costich T, Payne K, Biswas S, Harro C . TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022; 55(1):115-128.e9. PMC: 8852221. DOI: 10.1016/j.immuni.2021.12.007. View

Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A . Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007; 56(9):1459-69. PMC: 11030123. DOI: 10.1007/s00262-007-0286-3. View

Lee H, Kim J, Park I, Song I, Yu J, Ahn J . Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. Am J Clin Pathol. 2015; 144(2):278-88. DOI: 10.1309/AJCPIXUYDVZ0RZ3G. View

Cipponi A, Mercier M, Seremet T, Baurain J, Theate I, van den Oord J . Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 2012; 72(16):3997-4007. DOI: 10.1158/0008-5472.CAN-12-1377. View

Song I, Heo S, Bang W, Park H, Park I, Kim Y . Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat. 2016; 49(2):399-407. PMC: 5398384. DOI: 10.4143/crt.2016.215. View

Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K . Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015; 16(12):1235-44. PMC: 4653079. DOI: 10.1038/ni.3290. View

Meshcheryakova A, Tamandl D, Bajna E, Stift J, Mittlboeck M, Svoboda M . B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One. 2014; 9(6):e99008. PMC: 4048213. DOI: 10.1371/journal.pone.0099008. View

10.

Girard J, Moussion C, Forster R . HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol. 2012; 12(11):762-73. DOI: 10.1038/nri3298. View

11.

Stowman A, Hickman A, Mauldin I, Mahmutovic A, Gru A, Slingluff Jr C . Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res. 2018; 28(3):237-245. PMC: 5912978. DOI: 10.1097/CMR.0000000000000439. View

12.

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

13.

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

14.

Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E . Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022; 40(3):318-334.e9. DOI: 10.1016/j.ccell.2022.01.002. View

15.

Ladanyi A, Somlai B, Gilde K, Fejos Z, Gaudi I, Timar J . T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004; 10(2):521-30. DOI: 10.1158/1078-0432.ccr-1161-03. View

16.

Pinter M, Jain R, Duda D . The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2020; 7(1):113-123. PMC: 8265820. DOI: 10.1001/jamaoncol.2020.3381. View

17.

Gould S, Isaacson P . Bronchus-associated lymphoid tissue (BALT) in human fetal and infant lung. J Pathol. 1993; 169(2):229-34. DOI: 10.1002/path.1711690209. View

18.

Lee A, Gillett C, Ryder K, Fentiman I, Miles D, Millis R . Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology. 2006; 48(6):692-701. DOI: 10.1111/j.1365-2559.2006.02410.x. View

19.

Jones E, Gallimore A, Ager A . Defining High Endothelial Venules and Tertiary Lymphoid Structures in Cancer. Methods Mol Biol. 2018; 1845:99-118. DOI: 10.1007/978-1-4939-8709-2_7. View

20.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View